The license adds to 3M’s range of inhalation technologies, giving the company an additional platform to use in the formulation of single and multi-unit dose devices.
Conix is cheaper than other inhalers and enables a large proportion of the drug to be effectively delivered to the lungs, according to Cambridge Consultants.